MYOCURE: Development of an innovative gene therapy platform to cure rare hereditary muscle disorders

Countries involved


  • Belgium: 12.5%

  • France: 25.0%

  • Germany: 25.0%

  • Spain: 25.0%

  • Uk: 12.5%

Institutions involved


  • 4

    Universities

  • 1

    Research organisations

  • 3

    Enterprises

Gender distribution of principal investigators


  • 55.5%

    Women

  • 44.5%

    Men

Further facts and figures


  • 5.99M

    MYOCURE receives about EUR 5.99 million funding from the European Union’s Horizon 2020 Research and Innovation programme.

  • PHC-14-2015

    MYOCURE addresses the topic PHC-14-2015: ‘New therapies for rare diseases’ of the European Union’s Horizon 2020 framework programme.

  • 8

    MYOCURE involves 8 partner institutions from 5 different European countries.

  • 48

    MYOCURE has a duration of 48 months to achieve the objectives of the project.

  • 9

    The MYOCURE work plan is structured in 9 work packages each led by renown experts in the corresponding fields.

  • 400

    MYOCURE partners published around 400 peer-reviewed publications primarily in the gene therapy field.

  • 20.000

    MYOCURE will impact directly on an estimated 20.000 people in the EU suffering from MTM or GSD II.

  • 200

    MYOCURE will contribute to the IRDiRC objective of achieving 200 new therapies for rare diseases by year 2020.